Science News
from research organizations

Reactivation of AKT survival pathway by ERK1/2

Date:
January 7, 2014
Source:
Landes Bioscience
Summary:
In the study by Toulany et al., it was demonstrated for the first time that long term treatment with inhibitors of PI3K (as it is performed clinically) results in a reactivation of the major survival component Akt through a so far unknown regulatory loop via ERK1/2.
Share:
       
FULL STORY

In a study by Toulany et al., it was demonstrated for the first time that long term treatment with inhibitors of PI3K (as it is performed clinically) results in a reactivation of the major survival component Akt through a so far unknown regulatory loop via ERK1/2.

This reactivation of Akt limits quite efficiently the response of the tested tumor cell lines presenting constitutively active K-Ras activity (both through K-RAS mutation or over-expression of K-RAS wildtype) to antagonistic strategies directed against PI3K. Thus, the described ERK1/2 dependency of reactivation of Akt gives new insights into the underlying mechanisms of resistance accompanying EGFR and PI3K antagonizing strategies.

Moreover and clinically perhaps even more importantly, these findings provide specific hints how the combination of MEK-ERK1/2 and PI3K inhibitors can efficiently be used to overcome therapy resistance of tumors presenting constitutively high K-Ras activity.


Story Source:

The above story is based on materials provided by Landes Bioscience. Note: Materials may be edited for content and length.


Cite This Page:

Landes Bioscience. "Reactivation of AKT survival pathway by ERK1/2." ScienceDaily. ScienceDaily, 7 January 2014. <www.sciencedaily.com/releases/2014/01/140107093325.htm>.
Landes Bioscience. (2014, January 7). Reactivation of AKT survival pathway by ERK1/2. ScienceDaily. Retrieved May 29, 2015 from www.sciencedaily.com/releases/2014/01/140107093325.htm
Landes Bioscience. "Reactivation of AKT survival pathway by ERK1/2." ScienceDaily. www.sciencedaily.com/releases/2014/01/140107093325.htm (accessed May 29, 2015).

Share This Page: